SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1651 226X srt2:(2010-2014)"

Sökning: L773:1651 226X > (2010-2014)

  • Resultat 1-10 av 218
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  • Aamand Grabau, Dorthe, et al. (författare)
  • The prevalence of immunohistochemically determined oestrogen receptor positivity in primary breast cancer is dependent on the choice of antibody and method of heat-induced epitope retrieval - prognostic implications?
  • 2013
  • Ingår i: Acta Oncologica. - : Informa Healthcare. - 0284-186X .- 1651-226X. ; 52:8, s. 1657-1666
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. Oestrogen receptor (ER) status is important for the choice of systemic treatment of breast cancer patients. However, most data from randomised trials on the effect of adjuvant endocrine therapy according to ER status are based on the cytosol methods. Comparisons with immunohistochemical methods have given similar results. The aim of the present study was to examine whether different ER antibodies and heat-induced epitope retrieval (HIER) methods influence the prevalence of ER-positivity in primary breast cancer. Material and methods. This study is based on patients included in a clinical trial designed to compare the effect of two years of adjuvant tamoxifen versus no adjuvant systemic treatment in premenopausal women. From 1986 to 1991, 564 patients from two study centres in Sweden were enrolled and randomised. Patients were randomised independently of ER status. In the present study, ER status was assessed on tissue microarrays with the three different ER antibody/HIER combinations: 1D5 in citrate pH 6 (n = 390), SP1 in Tris pH 9 (n = 390) and PharmDx in citrate pH 6 (n = 361). Results. At cut-offs of 1% and 10%, respectively, the prevalence of ER-positivity was higher with SP1 (75% and 72%) compared with 1D5 (68% and 66%) and PharmDx (66% and 62%). At these cut-offs, patients in the discordant groups (SP1-positive and 1D5-negative) seem to have a prognosis intermediate between those of the double-positive and double-negative groups. Comparison with the ER status determined by the cytosol-based methods in the discordant group also showed an intermediate pattern. The repeatability was good for all antibodies and cut-offs, with overall agreement andgt;= 93%. Conclusion. The present study shows that the choice of antibody and HIER method influences the prevalence of ER-positivity. We suggest that this be taken into consideration when choosing a cut-off for clinical decision making.
  •  
3.
  • Adami, HO (författare)
  • The prostate cancer pseudo-epidemic
  • 2010
  • Ingår i: Acta oncologica (Stockholm, Sweden). - : Informa UK Limited. - 1651-226X .- 0284-186X. ; 49:3, s. 298-304
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
4.
  • Adolfsson, J (författare)
  • Screening for prostate cancer - will we ever know?
  • 2010
  • Ingår i: Acta oncologica (Stockholm, Sweden). - : Informa UK Limited. - 1651-226X .- 0284-186X. ; 49:3, s. 275-277
  • Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
  •  
5.
  • Al-Olama, Mohamed, et al. (författare)
  • The peptide AF-16 decreases high interstitial fluid pressure in solid tumors.
  • 2011
  • Ingår i: Acta oncologica (Stockholm, Sweden). - 1651-226X.
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract Background. The high interstitial fluid pressure (IFP) in solid tumors restricts the access to nutrients, oxygen and drugs. Material and methods. We investigated the ability of the peptide AF-16, involved in water and ion transfer through cell membranes, to lower the IFP in two different solid rat mammary tumors, one chemically induced, slowly growing, and the other transplantable, and rapidly progressing having high cellularity. AF-16 was administered either in the tumor capsule, intranasally or intravenously. The IFP was measured by a miniature fiber optic device. Results. AF-16 significantly lowered the IFP in both the slowly and the rapidly progressing tumors, whether administrated locally or systemically. The AF-16 induced IFP reduction was maximal after 90 min, lasted at least 3 h, and returned to pretreatment levels in less than 24 h. Topical AF-16 transiently reduced the IFP in the DMBA tumors from 17.7 ± 4.2 mmHg to 8.6 ± 2.1 mmHg. Conclusion. We conclude that AF-16 transiently and reversibly lowered the high IFP in solid tumors during a few hours, which might translate into improved therapeutic efficacy.
  •  
6.
  • Albrow, Rebecca, et al. (författare)
  • Interventions to improve cervical cancer screening uptake amongst young women : A systematic review
  • 2014
  • Ingår i: Acta Oncologica. - London : Informa Healthcare. - 0284-186X .- 1651-226X. ; 53:4, s. 445-451
  • Forskningsöversikt (refereegranskat)abstract
    • Objectives. In view of declining screening uptake in young women, this review aims to summarise the available evidence relating to interventions designed to increase cervical screening uptake amongst women aged <= 35 years.Methods. Electronic databases were searched and further articles located by manual searches. Study designs employing a valid comparison group and including women aged <= 35 years published through 2012 were considered. Data was extracted on the uptake from either screening programme statistics or as reported by the study subjects. A narrative synthesis was undertaken for each category of interventions identified.Results. Ninety-two records were screened with 36 articles retrieved for further assessment. Four studies met the inclusion criteria, two of which evaluated more than one intervention. One of the studies evaluated the use of a modified invitation letter and reported no significant increase in uptake compared to a standard invitation. Three studies investigated the use of a reminder letter, with two reporting a positive effect on screening uptake in women aged 24-34. Three studies were included which supported the use of physician and telephone reminders. One study on HPV self-sampling reported a positive effect when compared with a reminder letter.Conclusions. There is a lack of randomised controlled trials designed to specifically address falling cervical screening uptake in amongst young women. Cervical screening programmes need to look beyond the use of invitation/reminders letters in this group of women to develop interventions which attempt to overcome as many barriers to uptake as possible.
  •  
7.
  • Alevronta, Eleftheria, et al. (författare)
  • Dose-response relationships for an atomized symptom of fecal incontinence after gynecological radiotherapy.
  • 2013
  • Ingår i: Acta oncologica (Stockholm, Sweden). - : Taylor & Francis. - 1651-226X .- 0284-186X. ; 52:4, s. 719-26
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose. The aim of this study was to investigate what bowel organ and delivered dose levels are most relevant for the development of 'emptying of all stools into clothing without forewarning' so that the related dose-responses could be derived as an aid in avoiding this distressing symptom in the future. Material and methods. Of the 77 gynecological cancer survivors treated with radiotherapy (RT) for gynecological cancer, 13 developed the symptom. The survivors were treated between 1991 and 2003. The anal-sphincter region, the rectum, the sigmoid and the small intestines were all delineated and the dose-volume histograms were exported for each patient. The dose-volume parameters were estimated fitting the data to the Relative Seriality (RS), the Lyman and the generalized Equivalent Uniform Dose (gEUD) model. Results. The dose-response parameters for all three models and four organs at risk (OARs) were estimated. The data from the sigmoid fits the studied models best: D50 was 58.8 and 59.5 Gy (RS, Lyman), γ50 was 1.60 and 1.57 (RS, Lyman), s was 0.32, n was 0.13 and a was 7.7 (RS, Lyman, gEUD). The estimated volume parameters indicate that the investigated OARs behave serially for this endpoint. Our results for the three models studied indicate that they have the same predictive power (similar LL values) for the symptom as a function of the dose for all investigated OARs. Conclusions. In our study, the anal-sphincter region and sigmoid fit our data best, but all OARs were found to have steep dose-responses for 'emptying of all stools into clothing without forewarning' and thus, the outcome can be predicted with an NTCP model. In addition, the dose to the four studied OARs may be considered when minimizing the risk of the symptom.
  •  
8.
  • Alsadius, David, 1975, et al. (författare)
  • Partnership status affects the association between gastrointestinal symptoms and quality of life after radiation therapy for prostate cancer.
  • 2014
  • Ingår i: Acta oncologica (Stockholm, Sweden). - 1651-226X. ; 53:3, s. 378-384
  • Tidskriftsartikel (refereegranskat)abstract
    • Purpose. To study if partnership modifies the effect of gastrointestinal symptoms on quality of life after radiation therapy for prostate cancer. Material and methods. Using a study-specific questionnaire we conducted a cross-sectional follow-up of the occurrence gastrointestinal symptoms and quality of life after radiation therapy for prostate cancer. We obtained information from 874 prostate cancer survivors treated with radiation therapy at the Sahlgrenska University Hospital, Sweden between 1994 and 2006. In this paper we describe how partnership status affects the association between gastrointestinal symptoms and quality of life. Results. We found that unpartnered men with gastrointestinal symptoms reported a lower quality of life than unpartnered men without such symptoms. Unpartnered men with symptoms had an excess risk of low quality of life compared with unpartnered men without symptoms for those experiencing altered composition of stools, prevalence ratio 3.8 (95% CI 1.1-13.1), leakage, 3.6 (1.3-10.1), sensory bowel symptoms, 4.5 (1.6-12.8), and for urgency, 4.2 (1.2-15.1). We also found that unpartnered men with symptoms had an excess risk of low quality of life compared with partnered men with symptoms for those experiencing altered composition of stools, prevalence ratio 2.9 (95% CI 1.4-5.8), leakage 2.8 (1.2-6.4), sensory bowel symptoms 3.4 (1.5-7.4), urgency 2.6 (1.2-5.8), and for any gastrointestinal symptom 2.5 (1.3-4.9). Conclusion. Unpartnered men may represent a group that is specifically vulnerable to the distressful effects of gastrointestinal symptoms after radiation therapy for prostate cancer.
  •  
9.
  •  
10.
  • Andersson, Kristin, et al. (författare)
  • The interface of population-based cancer registries and biobanks in etiological and clinical research : current and future perspectives
  • 2010
  • Ingår i: Acta Oncologica. - 0284-186X .- 1651-226X. ; 49:8, s. 1227-1234
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: The availability of quality assured, population-based cancer registries and biobanks with high quality samples makes it possible to conduct research on large samples sets with long follow-up within a reasonable time frame. Defined quality for both cancer registries and biobanks is essential for enabling high quality biobank-based research. Recent networking projects have brought these infrastructures together to promote the combined use of cancer registries and biobanks in cancer research.MATERIALS AND METHODS: In this report we review the current status and future perspectives of cancer registries and biobanks and how the interface between them should be developed to optimally further cancer research.RESULTS AND DISCUSSION: Major conclusions for future improvements are that the research exploiting cancer registries and biobanks, and the research that is building and optimising the infrastructure, should evolve together for maximally relevant progress. Population-based and sustainable biobanks that continuously and consecutively store all samples ("Biological registries") under strict quality control are needed. There is also a need for increased education, information and visibility of the interdisciplinary sciences required for optimal exploitation of these resources.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 218
Typ av publikation
tidskriftsartikel (207)
forskningsöversikt (11)
Typ av innehåll
refereegranskat (200)
övrigt vetenskapligt/konstnärligt (18)
Författare/redaktör
Glimelius, Bengt (17)
Steineck, Gunnar, 19 ... (10)
Henriksson, Roger (10)
Toma-Daşu, Iuliana (8)
Dasu, Alexandru (8)
Nilsson, Per (6)
visa fler...
Nordin, Karin (6)
Bergkvist, Leif (6)
Fjällskog, Marie Lou ... (5)
Nygren, Peter (5)
Ahlgren, Johan (5)
Olsson, Caroline, 19 ... (4)
Strang, Peter (4)
Johansen, Christoffe ... (4)
Widmark, Anders (4)
Nilsson, Kristina (4)
Bjartell, Anders (4)
Sundin, Anders (4)
Holmqvist, Marit (4)
Johansson, Birgitta (4)
Tishelman, Carol (4)
Johansson, Karl-Axel (4)
Janson, Eva Tiensuu (4)
Engellau, Jacob (4)
Salander, Pär, 1948- (4)
Asklund, Thomas (4)
Börjeson, Sussanne (4)
Molin, Daniel (3)
Hagberg, Hans (3)
Holmberg, Lars (3)
Hedman, Håkan (3)
Johansson, Birgitta, ... (3)
Bergqvist, Michael (3)
Lambe, Mats (3)
Öberg, Kjell (3)
Johansson, Eva (3)
Ekman, Simon (3)
Nilsson, Cecilia (3)
Isacsson, Ulf (3)
Lennernäs, Bo, 1963 (3)
Berglund, Åke (3)
Waldenström, Ann-Cha ... (3)
Lampic, Claudia (3)
Langius-Eklöf, Ann (3)
Lindman, Henrik (3)
Welin, Staffan (3)
Alsadius, David, 197 ... (3)
Mahteme, Haile (3)
Lax, Ingmar (3)
Bergström, Stefan (3)
visa färre...
Lärosäte
Karolinska Institutet (117)
Uppsala universitet (84)
Lunds universitet (48)
Umeå universitet (38)
Göteborgs universitet (34)
Linköpings universitet (29)
visa fler...
Örebro universitet (9)
Stockholms universitet (8)
Chalmers tekniska högskola (2)
Marie Cederschiöld högskola (2)
Högskolan Kristianstad (1)
Kungliga Tekniska Högskolan (1)
Jönköping University (1)
Linnéuniversitetet (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (218)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (139)
Samhällsvetenskap (8)
Teknik (2)
Naturvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy